Develops an oral, non-hormonal treatment for pattern hair loss in men and women.
10-K for FY2025, filed Mar 30, 2026We are a dermatologist-founded, late clinical-stage biopharmaceutical company, or the “Company,” “we,” “us,” or “our”, focused on…View ↗
We are developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic…View ↗
VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration…View ↗
If approved, the company plans to sell directly to patients through a cash-pay model, with access through pharmacies, telehealth, direct mail and provider dispensing.
10-Q for Q3 FY2026, filed Nov 10, 2026
−$21MView ↗
Loading...